Residents of the MSU research park developed a unique treatment for battling sepsis. It has successfully passed all clinical trials and is soon expected to be available for use in hospitals. The new treatment is based on polymer sorbents derived for the first time.
The press office of the university reported that scientists have developed a novel method for deriving porous polymers of irregular structure, aimed at removing blood lipopolysaccharides, which are responsible for development of this malignant process.
“The structure is the following: porous spherical microgranules of hypercrosslinked styrene-divinylbenzene copolymer is used as a matrix. The surface of pores of microgranules has a covalently immobilized synthetic ligand to “Lipid A”, which is the most conserved domain of bacterial lipopolysaccharide. The proposed materials were chosen on the basis of safety, resistance to sterilization, absence of emission of low molecular weight compounds. Such matrix is characterized by high hemocompatibility, optimal morphology of pores (high proportion of mesopores to volume), and easiness of surface modification. Meanwhile ligand is characterized by strength of a bond to a lipopolysaccharide molecule” commented one of the developers, Ivan Bessonov.
Thуmedical device is a cylindrical plastic case, filled with the sorbent, that has standard ports for connection with blood tubing sets (“adsorber”, “adsorption column”).
With the help of a specialized pump, patient’s blood under a low pressure is filtered through the sorbent, while the blood cells and large plasma proteins are able to pass through without retention. Meanwhile, lipopolysaccharides are bound to specialized segments of sorbent surface.
Thereby, the purified blood is returned to the circulatory system, while the toxic substances, tightly bound by the sorbent, are removed from the organism.
The press office stated that thus far the production of the polymer sorbent and other component parts for manufacturing the adsorbers has been initialized. Independent accredited laboratories have conducted technical and toxicity experiment both in vivo and in vitroto test for biocompatibility and absence of toxic substances in materials that are utilized, and the efficiency of lipopolysaccharide adsorption. Poszdravnadzor conducted an expertise of experiment protocols and technological documentation, and allowed their use in clinical practice, recognizing them as safe and corresponding to the claimed characteristics.
The effectiveness of this extracorporeal blood filtration (selective hemosorption of lipopolysaccharides) is further confirmed by its recent inclusion in a pricelist of compulsory medical insurance in Moscow, Saint-Petersburg, and other regions.
“This method has already become a part of an insured medicine system. The company’s upcoming plans include new developments in the area of sorption technologies for blood filtration, and new products based on it, as well as extended (post registration) clinical trials on already existing products” commented the press office.